Trial intelligence / Profile preview

SPIRE-FH: Bococizumab in Heterozygous Familial Hypercholesterolemia

NCT01968980Phase 3Completed

Sponsor
Pfizer
Start
Oct 2013
Primary completion
Apr 2016
Modality
Recombinant Proteins and Enzymes, Monoclonal Antibodies
Countries
11
01

Overview

A Phase 3 trial of bococizumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Pfizer. Started Oct 2013; status: completed.

02

Drugs

bococizumab
03

Conditions

heterozygous familial hypercholesterolemia (HeFH)

Beyond the preview

Go deeper on NCT01968980.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01968980.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call